Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma
Crossref DOI link: https://doi.org/10.1007/s00280-016-3180-x
Published Online: 2016-11-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Flerlage, Jamie E.
Metzger, Monika L.
Wu, Jianrong
Panetta, John C.
Funding for this research was provided by:
NIH Cancer Center Support Grant (CA21765)
American Lebanese Syrian Associated Charities
License valid from 2016-11-11